Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Combined Phase II/III, Observer-Blind, Randomized, Multi-center Study to Evaluate Safety, Tolerability and Immunogenicity of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs, in Healthy Children and Adolescents

NCT00645411 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00645411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00645411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Combined Phase II/III, Observer-Blind, Randomized, Multi-center Study to Evaluate Safety, Tolerability and Immunogenicity of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs, in Healthy Children and Adolescents
Lead sponsor
Novartis
Phase
Phase 2/3
Overall status
Completed
Start date
October 31, 2007
Completion date
July 31, 2008
Enrollment
3,604 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

influenza